Tamman, Amanda J. F. http://orcid.org/0000-0002-3620-6698
Koller, Dora
Nagamatsu, Sheila
Cabrera-Mendoza, Brenda http://orcid.org/0000-0003-4729-9997
Abdallah, Chadi http://orcid.org/0000-0001-5783-6181
Krystal, John H. http://orcid.org/0000-0001-6952-1726
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Montalvo-Ortiz, Janitza L. http://orcid.org/0000-0002-7657-8365
Polimanti, Renato http://orcid.org/0000-0003-0745-6046
Pietrzak, Robert H.
Funding for this research was provided by:
U.S. Department of Veterans Affairs (None)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (#U01AG032284)
Article History
Received: 23 May 2023
Revised: 25 August 2023
Accepted: 25 September 2023
First Online: 17 October 2023
Change Date: 5 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41386-023-01786-y
Competing interests
: This manuscript contains original research, has not been published elsewhere and has not been submitted simultaneously for publication elsewhere. We have the following disclosures to report: JG is named as an inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. JG and RP are paid for their editorial work on the journal Complex Psychiatry. RP received a research grant from Alkermes. JHK has served as a scientific consultant to the following companies (the Individual Consultant Agreements listed are less than $5000 per year): AMGEN; AstraZeneca Pharmaceuticals; Bigen, Idec, MA; Biomedisyn Corporation; Forum Pharmaceuticals; Janssen Research & Development; Otsuka America Pharmaceutical, Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Industries; Taisho Pharmaceutical Co., Ltd. He is on the Scientific Advisory Board for the following companies: Biohaven Pharmaceuticals; Blackthorn Therapeutics,Inc.; Lohocla Research Corporation; Luc Therapeutics, Inc.; Pfizer Pharmaceuticals; TRImaran Pharma. He holds stock in Biohaven Pharmaceuticals Medical Sciences and stock options in Blackthorn Therapeutics, Inc. and Luc Therapeutics, Inc. He is the editor of Biological Psychiatry (Income greater than $10,000). CGA has served as a consultant and/or on advisory boards for Aptinyx, Genentech, Janssen, Psilocybin Labs, Lundbeck, Guidepoint, and FSV7, and as editor of Chronic Stress for Sage Publications, Inc. He also filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (Aug 20, 2018). AJFT, BCM, DK, RHP, SN, and JLMO reported no biomedical financial interest.